Figure 4 is a diagram showing the design of the Heart and Estrogen/Progestin Replacement Study (HERS) and HERS II trials. HERS had an estrogen plus progestin versus placebo intervention phase lasting 4.1 years. The outcomes reported were mortality; breast, colorectal, lung, and endometrial cancer; diabetes; cognitive function; fractures; coronary heart disease; thromboembolic disease (deep vein thrombosis or pulmonary embolism); and urinary incontinence. The diagram also shows the HERS II postintervention phase, which includes the estrogen plus progestin versus placebo arm and reports 6.8 years of cumulative data. The outcomes reported were mortality; breast, colorectal, lung, and endometrial cancer; fractures; coronary heart disease; and thromboembolic disease (deep vein thrombosis or pulmonary embolism).

Figure 4Design of Heart and Estrogen/Progestin Replacement Study (HERS) and HERS II Trials

Abbreviations: CHD=coronary heart disease; DVT=deep vein thrombosis; E=estrogen; HERS/HERS II=Heart and Estrogen/Progestin Replacement Study; P=progestin; PE=pulmonary embolus.

From: 3, RESULTS

Cover of Menopausal Hormone Therapy for the Primary Prevention of Chronic Conditions
Menopausal Hormone Therapy for the Primary Prevention of Chronic Conditions: Systematic Review to Update the 2002 and 2005 U.S. Preventive Services Task Force Recommendations.
Evidence Syntheses, No. 93.
Nelson HD, Walker M, Zakher B, et al.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.